- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05386953
Intraoperativ administrering av normal koksaltlösning och akut njurskada hos patienter som genomgår levertransplantation
Intraoperativ administrering av normal koksaltlösning och akut njurskada hos patienter som genomgår levertransplantation: en retrospektiv kohortstudie
The investigators attempted to investigate the association of the type of crystalloid administered during liver transplantation with postoperative clinical outcomes. The investigators hypothesized that the greater amount of normal saline or half-saline administered during liver transplantation might be associated with the increased risk of acute kidney injury compared to the balanced crystalloids.
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
Liver transplantation requires a long operation time and is often associated with a significant amount of surgical bleeding. It is common for the anesthesiologist to infuse large amounts of fluid or blood products due to bleeding, hemodynamic instability, or ascites drainage. Therefore, in the anesthesia for liver transplantation, optimal management of fluid administration is necessary and the choice of the type of crystalloid may affect the prognosis or the incidence of postoperative complications of patients.
The investigators attempted to investigate the association of the type of crystalloid administered during liver transplantation with postoperative clinical outcomes. The investigators hypothesized that the greater amount of normal saline or half-saline administered during liver transplantation might be associated with the increased risk of acute kidney injury compared to the balanced crystalloids.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
-
Seoul, Sydkorea, 03080
- Seoul National University Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Patients received liver transplantation surgery in a single tertiary care university hospital
Beskrivning
Inclusion Criteria:
- Consecutive patients who underwent living or deceased donor liver transplantation at our tertiary care university hospital between 2004 and 2018
Exclusion Criteria:
- patients with baseline renal dysfunction of hepatorenal syndrome or chronic kidney disease
- missing preoperative serum creatinine value
- missing other baseline or outcome variables
- patients who received retransplantation
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: RETROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Balanced group
Patients who received balanced crystalloids of lactated Ringer's solution or plasma solution during liver transplantation surgery |
Patients received balanced crystalloids such as lactated Ringer's solution or Plasma solution as a maintenance crystalloid during liver transplantation surgery.
Andra namn:
|
|
Saline group
Patients who received only normal saline during liver transplantation surgery |
Patients received normal saline as a maintenance crystalloid during liver transplantation surgery. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Acute kidney injury
Tidsram: the first 7 postoperative days
|
The investigators defined acute kidney injury by the KDIGO (Kidney Disease Improving Global Outcomes) criteria, which was determined according to the greatest change in serum creatinine level during the postoperative seven days (Stage 1: more than 1.5-fold; stage 2: more than 2-fold; stage 3: more than 3-fold increase of baseline or increase in SCr to ≥ 4.0 mg/dL or the initiation of renal replacement therapy). The most recent SCr level measured before surgery was collected as a baseline value. |
the first 7 postoperative days
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of postoperative hemodialysis
Tidsram: the first month after admission
|
the incidence of new-onset postoperative hemodialysis during hospitalization |
the first month after admission
|
|
Early allograft dysfunction
Tidsram: the first 7 postoperative days
|
One or more of the following are present within the first 7 postoperative days: total bilirubin ≥ 10 mg/dL, PT (prothrombin time):INR (international normalized ratio)≥ 1.6, or AST (aspartate aminotransferase)/ALT (alanine aminotransferase) > 2000 IU/L |
the first 7 postoperative days
|
|
In-hospital mortality
Tidsram: the first month after admission
|
all-cause mortality during hospitalization |
the first month after admission
|
|
One-year mortality
Tidsram: one year after transplantation
|
all-cause mortality during one year after transplantation |
one year after transplantation
|
|
Length of intensive care unit stay
Tidsram: the first month after admission
|
Length of intensive care unit stay after transplantation |
the first month after admission
|
|
Length of hospital stay
Tidsram: the first month after admission
|
Length of hospital stay after transplantation |
the first month after admission
|
Samarbetspartners och utredare
Utredare
- Studiestol: Won Ho Kim, MD, PhD, Department of Anaesthesiology and Pain Medicine, Seoul National University Hospital
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Patologiska processer
- Matsmältningssystemets sjukdomar
- Leversjukdomar
- Leversvikt
- Leverinsufficiens
- Fibros
- Patologiska tillstånd, tecken och symtom
- Levercirros
- Slutstadiet leversjukdom
- Farmaceutiska förberedelser
- Kristalloidlösningar
- Isotonlösningar
- Lösningar
- Saltlösning
- Ringers laktat
- stable plasma protein solution
Andra studie-ID-nummer
- H-2108-173-1248
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .